top of page

Search Results

Search this site

658 results found with an empty search

  • CordenPharma invests €80m to expand sterile injectable capacity to 500m units annually

    CordenPharma is investing €80 million to expand aseptic fill-finish operations at its Caponago site in Italy, increasing projected sterile injectable capacity to up to 500 million units annually. The expansion will add new aseptic filling lines and strengthen CordenPharma's ability to manufacture and package sterile injectable medicines for pharmaceutical and biotechnology customers. The investment reflects growing demand for outsourced sterile manufacturing capacity and forms part of the company's broader strategy to scale high-value injectable drug production across its global network. Field Content Alert Type Industry Update Company CordenPharma Development Type Manufacturing capacity expansion Investment €80 million Facility Caponago manufacturing site Location Italy Manufacturing Area Aseptic fill-finish; sterile injectables Projected Capacity Up to 500 million sterile injectable units annually What Happened CordenPharma announced an €80 million investment to expand aseptic fill-finish capacity at its Caponago facility in Italy. Why It Matters The expansion substantially increases sterile injectable manufacturing capacity at a time of strong demand for outsourced aseptic production services. Supporting Context The programme includes additional aseptic filling infrastructure designed to support pharmaceutical and biotechnology customers across multiple injectable formats. Strategic Rationale CordenPharma is scaling high-value sterile manufacturing capabilities to strengthen its position as a global contract development and manufacturing partner. Potential Impact The added capacity could support greater commercial supply volumes and provide drug developers with additional European sterile manufacturing options. Key Takeaway CordenPharma is investing €80 million to scale its Italian sterile injectable operations toward 500 million units of annual capacity. What to Watch Completion of the new filling lines, customer onboarding and utilisation of the expanded Caponago capacity. Primary Source CordenPharma Relevant Date 10 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Lupin receives Indian marketing approval for pegfilgrastim biosimilar

    Lupin has received Indian marketing approval for a pegfilgrastim biosimilar used to reduce the risk of chemotherapy-induced neutropenia. The approval expands Lupin's biosimilar portfolio in oncology supportive care and provides another locally manufactured treatment option for patients receiving myelosuppressive chemotherapy. Pegfilgrastim is a long-acting granulocyte colony-stimulating factor used to reduce the incidence and duration of neutropenia and related infection risk following cancer treatment. Field Content Alert Type Approval Drug Name Pegfilgrastim biosimilar Company Lupin Regulatory Authority Indian regulatory authorities Approval Type Marketing approval Indication Reduction of chemotherapy-induced neutropenia in patients receiving myelosuppressive anticancer treatment Therapy Area(s) Oncology; supportive care Technology or Modality Biosimilar; granulocyte colony-stimulating factor Geography India What Happened Lupin received marketing approval in India for its pegfilgrastim biosimilar. Why It Matters The approval adds another biosimilar option in oncology supportive care and expands access to long-acting neutropenia prevention for patients receiving chemotherapy. Supporting Context Pegfilgrastim is a long-acting granulocyte colony-stimulating factor used to stimulate neutrophil production following myelosuppressive chemotherapy. Key Takeaway Lupin has added an approved pegfilgrastim biosimilar to its Indian oncology supportive-care portfolio. What to Watch Commercial launch, physician uptake and pricing relative to existing pegfilgrastim products in India. Primary Source ETPharma.com Relevant Date 10 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • How Much Do Gastrointestinal Surgeons Earn in Japan? 2025 Physician Income Data

    Gastrointestinal surgeons in Japan reported a median annual income of ¥19 million (approximately £91,000) in the latest specialty-level physician income survey from the Physician Career Research Institute. The 2025 survey, based on responses from 2,055 physicians overall, provides a useful benchmark for gastrointestinal surgeons assessing their own professional earnings in Japan. Among gastrointestinal surgery respondents: Median annual income: ¥19 million (approximately £91,000) Proportion earning ¥20 million or more: 42.86% ¥20 million threshold: approximately £96,000 Gastrointestinal surgery respondents: 70 Importantly, these figures include income from a physician’s main workplace as well as additional or side work. For gastrointestinal surgeons, that distinction is central to understanding the headline compensation figure. What is the median income for a gastrointestinal surgeon in Japan? The reported median annual income for gastrointestinal surgeons was: ¥19 million (approximately £91,000) This should be interpreted as total annual professional income including side work, rather than simply the salary paid by a surgeon’s primary hospital or employer. That matters because physicians in Japan may earn income from more than one clinical position. A gastrointestinal surgeon may have a principal hospital appointment while also undertaking additional paid clinical work elsewhere. The ¥19 million figure is therefore most useful as a benchmark for total professional earnings. It should not be interpreted as an expected base salary. 42.86% of gastrointestinal surgeons reported earning ¥20 million or more The survey provides another important benchmark for gastrointestinal surgeons: 42.86% reported annual income of ¥20 million or more (approximately £96,000+). That means more than four in ten gastrointestinal surgeons included in the survey reported total annual professional income at or above this level. For a gastrointestinal surgeon reviewing their own compensation, the two most useful figures are therefore: Median annual income: ¥19 million (approximately £91,000) Earning ¥20 million+ (approximately £96,000+): 42.86% Together, these provide a practical indication of the income levels reported within the specialty. Why does side work matter for gastrointestinal surgeon income? Additional professional work is an important consideration when interpreting physician earnings in Japan. Doctors may undertake paid clinical work outside their principal position, including additional shifts, sessions at other hospitals or clinics, or other secondary medical work. The Physician Career Research Institute therefore reports annual income including side work. For gastrointestinal surgeons, this means income from the main employer may not represent total annual earnings. A surgeon receiving less than ¥19 million from their primary hospital could still reach or exceed the survey benchmark once additional professional income is included. Equally, the data should not be interpreted as showing that gastrointestinal surgeons are routinely offered a ¥19 million basic salary. The figure represents a broader measure of professional income. What does the ¥19 million median actually mean? There is an important methodological point behind the reported figure. Survey respondents did not provide a precise annual earnings number. Instead, income was collected in bands. The reported median of ¥19 million (approximately £91,000) represents the midpoint of the ¥18 million–¥20 million income band. That means the figure should be treated as an approximate compensation benchmark rather than an exact mathematical median calculated from individual salary records. For a gastrointestinal surgeon using the survey to assess their own earnings, it may therefore be more useful to think of the benchmark as: roughly ¥18 million–¥20 million in total annual professional income rather than viewing ¥19 million as an exact expected amount. How strong is the gastrointestinal surgery sample? The wider survey included 2,055 physicians, with 70 respondents in gastrointestinal surgery. That provides a useful specialty-specific sample, although it remains survey evidence rather than a national census. Individual earnings may vary considerably depending on: career stage; seniority; employer; hospital setting; working hours; geographic location; additional clinical responsibilities; and the amount of side work undertaken. The figures are therefore most useful as a current benchmark rather than a guaranteed level of income. Is ¥19 million a gastrointestinal surgeon salary? No. The cleanest interpretation is: ¥19 million is the reported median total annual professional income for gastrointestinal surgeons in the survey, including side work. It is not a published base salary. For a gastrointestinal surgeon evaluating current earnings or considering another role, it can be useful to separate: guaranteed salary from the primary employer; additional paid clinical work; other professional income; and total annual earnings. The survey benchmark relates most closely to total annual professional income. What should gastrointestinal surgeons take from the latest data? For gastrointestinal surgeons in Japan, the 2025 survey provides two clear compensation benchmarks. Median annual professional income, including side work, was: ¥19 million (approximately £91,000) And: 42.86% of gastrointestinal surgeons reported earning ¥20 million or more (approximately £96,000+). For an individual gastrointestinal surgeon, these figures provide a useful reference point when assessing their own total annual professional income. The key is to compare like with like. A basic hospital salary should not be directly compared with a figure that includes additional clinical work. For gastrointestinal surgeons, the more useful question is therefore not simply: “What is a gastrointestinal surgeon’s salary in Japan?” It is: “What is my total annual professional income as a gastrointestinal surgeon, including additional clinical work, and how does it compare with the ¥19 million benchmark?” That is the most meaningful way to use the available gastrointestinal surgery compensation data. Source: Physician Career Research Institute / Mediwel, 2025 Physician Income Survey. Currency note: Sterling equivalents are approximate conversions using the JPY/GBP exchange rate on 11 September 2026. At that rate, ¥19 million is approximately £91,000 and ¥20 million approximately £96,000. GBP figures are included for reader context only and were not reported by the original Japanese survey. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • How Much Do Anesthesiologists Earn in Japan? 2025 Physician Income Data

    Anesthesiologists in Japan reported a median annual income of ¥19 million (approximately £91,000) in the latest specialty-level physician income survey from the Physician Career Research Institute. The 2025 survey, based on responses from 2,055 physicians overall, provides a useful benchmark for anesthesiologists assessing their own professional earnings in Japan. Among the anesthesiology respondents: Median annual income: ¥19 million (approximately £91,000) Proportion earning ¥20 million or more: 43.02% ¥20 million threshold: approximately £96,000 Anesthesiology respondents: 86 The figures include income from a physician’s main workplace as well as additional or side work. For anesthesiologists, that distinction is essential when interpreting the headline figure. What is the median income for an anesthesiologist in Japan? The reported median annual income for anesthesiologists was: ¥19 million (approximately £91,000) This figure represents total annual professional income including side work, rather than simply the salary received from a physician’s main hospital or clinic. That is important because physicians in Japan may receive income from more than one clinical position. For an anesthesiologist, the ¥19 million figure is therefore best viewed as a benchmark for overall professional earnings. It should not be interpreted as an expected base salary. 43.02% of anesthesiologists reported earning ¥20 million or more The survey provides a second useful benchmark for anesthesiologists: 43.02% of anesthesiology respondents reported annual income of ¥20 million or more (approximately £96,000+). That means more than four in ten anesthesiologists in the survey reported total professional income at or above this level. For an anesthesiologist reviewing their own compensation, the two most useful figures are therefore: Median annual income: ¥19 million (approximately £91,000) Earning ¥20 million+ (approximately £96,000+): 43.02% Together, they provide a clearer picture of the income level reported within the specialty. Why does side work matter for anesthesiologist income? Additional professional work is an important part of physician earnings in Japan. Doctors may undertake paid clinical work outside their main role, including shifts at other hospitals or clinics and other secondary medical work. The Physician Career Research Institute therefore reports annual income including side work. For anesthesiologists, this means income from a principal employer may not represent total annual compensation. An anesthesiologist receiving less than ¥19 million from their primary hospital could still reach or exceed the survey benchmark once additional professional earnings are included. Equally, the survey should not be interpreted as showing that anesthesiologists are routinely offered a ¥19 million basic salary. The figure reflects a broader measure of professional income. How should an anesthesiologist interpret the ¥19 million figure? There is an important methodological point behind the reported median. Respondents did not report a precise annual income figure. Instead, earnings were collected in income bands. The reported median of ¥19 million (approximately £91,000) represents the midpoint of the ¥18 million–¥20 million income band. That means the figure should be treated as an approximate compensation benchmark rather than an exact mathematical median calculated from precise salary records. For an anesthesiologist using the data to assess their own compensation, it may be more useful to think of the benchmark as: approximately ¥18 million–¥20 million in total annual professional income rather than treating ¥19 million as an exact expected figure. How strong is the anesthesiology sample? The wider survey included 2,055 physicians, with 86 respondents in anesthesiology. That provides a useful specialty-specific sample, although it is still survey evidence rather than a national census. Individual anesthesiologist earnings can vary depending on factors such as: career stage; seniority; employer; hospital or clinic setting; working hours; geographic location; on-call or additional clinical work; and the amount of side work undertaken. The figures are therefore most useful as a current market benchmark rather than a guaranteed expectation. Is ¥19 million an anesthesiologist salary? No. The cleanest interpretation is: ¥19 million is the reported median total annual professional income for anesthesiologists in the survey, including side work. It is not a published base salary. For an anesthesiologist considering a new role or evaluating current earnings, it is useful to separate: guaranteed salary from the principal employer; additional paid clinical work; supplementary professional income; and total annual earnings. The survey benchmark relates most closely to total annual professional income. What should anesthesiologists take from the latest data? For anesthesiologists in Japan, the 2025 survey provides two clear compensation benchmarks. Median annual professional income, including side work, was: ¥19 million (approximately £91,000) And: 43.02% of anesthesiologists reported earning ¥20 million or more (approximately £96,000+). For an individual anesthesiologist, these figures provide a useful reference point when considering overall professional earnings. The key is to compare like with like. A basic hospital salary should not be compared directly with a figure that includes additional professional work. For anesthesiologists, the more useful question is therefore not simply: “What is an anesthesiologist’s salary in Japan?” It is: “What is my total annual professional income as an anesthesiologist, including additional clinical work, and how does it compare with the ¥19 million benchmark?” That is the most meaningful way to use the available anesthesiology compensation data. Source: Physician Career Research Institute / Mediwel, 2025 Physician Income Survey. Currency note: Sterling equivalents are approximate conversions using the JPY/GBP exchange rate on 11 September 2026. At that rate, ¥19 million is approximately £91,000 and ¥20 million approximately £96,000. GBP figures are included for reader context only and were not reported by the original Japanese survey. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • How Much Do Cardiologists Earn in Japan? 2025 Physician Income Data

    Cardiologists in Japan reported a median annual income of ¥19 million (approximately £91,000) in the latest specialty-level physician income survey from the Physician Career Research Institute. The 2025 survey, based on responses from 2,055 physicians overall, provides a useful benchmark for cardiologists assessing their own professional earnings. Among the cardiology respondents: Median annual income: ¥19 million (approximately £91,000) Proportion earning ¥20 million or more: 44.00% ¥20 million threshold: approximately £96,000 Cardiology respondents: 75 Importantly, these figures include income from a cardiologist’s main workplace as well as additional or side work. For cardiologists looking at compensation in Japan, that distinction is central to understanding what the reported income figure actually represents. What is the median income for a cardiologist in Japan? The reported median annual income for cardiologists was: ¥19 million (approximately £91,000) This should be interpreted as total annual professional income including side work, rather than simply the salary paid by a cardiologist’s main hospital or clinic. That matters because physicians in Japan may receive income from more than one clinical role. A cardiologist may, for example, have a primary hospital position while also undertaking additional paid clinical work elsewhere. The ¥19 million figure is therefore best understood as a benchmark for total professional earnings. It should not be read as an expected base salary. 44% of cardiologists reported earning ¥20 million or more The survey provides another useful benchmark for cardiologists: 44.00% of cardiology respondents reported annual income of ¥20 million or more (approximately £96,000+). That means more than four in ten cardiologists in the survey reported total annual professional income at or above this level. For a cardiologist assessing their own compensation, the two most useful figures are therefore: Median annual income: ¥19 million (approximately £91,000) Earning ¥20 million+ (approximately £96,000+): 44.00% Together, these provide a practical indication of where an individual cardiologist’s total income may sit relative to the surveyed group. Why does side work matter for cardiologist income? One of the most important features of the survey is that it includes additional professional income. Physicians in Japan may undertake paid work outside their primary position, including additional shifts or clinical work at other hospitals and clinics. For cardiologists, this means that income from a principal employer may not tell the full story. A cardiologist receiving less than ¥19 million from their main hospital could still reach or exceed the reported median once other professional earnings are included. Equally, the survey does not mean that a hospital should be expected to offer a cardiologist a basic salary of ¥19 million. The figure represents a broader measure of annual professional income. For cardiologists evaluating their compensation, it can therefore be useful to separate: base salary from the main employer; additional clinical work; other professional income; and total annual earnings. The survey’s ¥19 million benchmark relates most closely to the final category. What does the ¥19 million median actually mean? There is an important methodological point behind the reported figure. Survey respondents did not provide one exact income number. Instead, income was collected in bands. The reported median of ¥19 million (approximately £91,000) represents the midpoint of the ¥18 million–¥20 million income band. That means the figure should be treated as an approximate benchmark rather than a precise mathematical median calculated from exact salary records. For cardiologists using the data to assess their own position, it may therefore be more useful to think of the benchmark as: roughly ¥18 million–¥20 million in total annual professional income rather than focusing too narrowly on ¥19 million as an exact amount. How strong is the cardiology sample? The wider survey included 2,055 physicians, with 75 respondents in cardiology. That provides a meaningful specialty-specific sample, although it is still a survey rather than a complete national census of cardiologists. The figures should therefore be used as an informed benchmark rather than a definitive statement of what every cardiologist in Japan earns. Individual income may vary depending on: career stage; seniority; employer; working hours; hospital or clinic setting; geographic location; and the amount of additional work undertaken. For a cardiologist, the value of the dataset is in providing a current reference point against which their own total annual income can be considered. Is ¥19 million a cardiologist salary? No. The cleanest interpretation is: ¥19 million is the reported median total annual professional income for the surveyed cardiologists, including side work. It is not a published base salary. That distinction becomes especially important when looking at a new employment opportunity. A cardiologist considering a new role may therefore want to ask: What is the guaranteed base salary? What additional paid clinical work is available? How much income is typically earned outside the principal role? What does realistic total annual professional income look like? Those questions provide a more meaningful comparison with the survey than base salary alone. What should cardiologists take from the latest data? For cardiologists in Japan, the 2025 survey provides two clear compensation benchmarks. Median annual professional income, including side work, was: ¥19 million (approximately £91,000) And: 44.00% of cardiologists reported earning ¥20 million or more (approximately £96,000+). For an individual cardiologist, these figures offer a useful reference point when assessing total annual earnings. The key is to compare like with like. A base hospital salary should not be compared directly with a figure that includes additional professional work. For cardiologists, the more useful question is therefore not simply: “What is a cardiologist’s salary in Japan?” It is: “What is my total annual professional income as a cardiologist, including additional clinical work, and how does it compare with the ¥19 million benchmark?” That is the most meaningful way to use the available cardiology compensation data. Source: Physician Career Research Institute / Mediwel, 2025 Physician Income Survey. Currency note: Sterling equivalents are approximate conversions using the JPY/GBP exchange rate on 11 September 2026. At that rate, ¥19 million is approximately £91,000 and ¥20 million approximately £96,000. GBP figures are included for reader context only and were not reported by the original Japanese survey. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • How Much Do Dialysis Physicians Earn in Japan? 2025 Physician Income Data

    Physicians working in dialysis medicine in Japan reported a median annual income of ¥19 million (approximately £91,000) in the latest specialty-level physician income survey from the Physician Career Research Institute. The 2025 survey, based on responses from 2,055 physicians overall, provides a rare specialty-specific benchmark for doctors working in dialysis medicine. Among the dialysis medicine respondents: Median annual income: ¥19 million (approximately £91,000) Proportion earning ¥20 million or more: 45.00% ¥20 million threshold: approximately £96,000 Dialysis medicine respondents: 20 The figures include income from a physician's main workplace as well as additional or side work. For a dialysis physician trying to understand how their own earnings compare with the available Japanese market data, that distinction is essential. What is the median income for a dialysis physician in Japan? The reported median annual income for dialysis medicine was: ¥19 million (approximately £91,000) This should be interpreted as total annual professional income including side work, rather than simply the salary paid by a physician's principal hospital or clinic. Physicians in Japan may earn income through more than one clinical role, so compensation from a primary employer does not necessarily represent their full annual earnings. For someone working in dialysis medicine, the ¥19 million figure is therefore best used as a benchmark for overall professional income. It should not be interpreted as an expected base salary. 45% of dialysis physicians reported earning ¥20 million or more The survey provides another important benchmark for physicians working in dialysis care. 45.00% of dialysis medicine respondents reported annual income of at least ¥20 million (approximately £96,000). That means almost half of the dialysis physicians included in the survey reported total professional earnings at or above this level. For an individual physician assessing their current compensation, these two figures can be considered together: Median annual income: ¥19 million (approximately £91,000) Earning ¥20 million+ (approximately £96,000+): 45.00% They provide a useful indication of the income distribution within the surveyed dialysis medicine group. Why does side work matter when looking at dialysis physician income? An important feature of the Japanese physician labour market is the role of additional clinical work. Doctors may work at more than one hospital or clinic, undertake additional shifts or receive income through other paid medical activity. The Physician Career Research Institute therefore reports annual physician income including side work. This matters when interpreting the dialysis medicine figure. A physician receiving less than ¥19 million from their main employer may still reach or exceed the survey benchmark once additional professional income is included. Equally, the survey does not suggest that a dialysis physician should expect a basic salary of ¥19 million. The figure reflects a wider definition of annual professional earnings. For dialysis physicians evaluating a role, it can therefore be useful to separate: income from the principal employer; additional clinical income; supplementary shifts or secondary positions; and total annual professional earnings. The ¥19 million benchmark relates most closely to the final category. How should a dialysis physician interpret the ¥19 million figure? There is an important methodological point behind the reported median. Physicians did not report their income as a precise individual number. Instead, the survey collected earnings in income bands. The reported median of ¥19 million (approximately £91,000) represents the midpoint of the relevant ¥18 million–¥20 million income range. It should therefore be viewed as an approximate compensation benchmark rather than an exact mathematical median calculated from precise salary records. For a physician using the survey to assess their own compensation, this means the figure is most useful as a reference range. Someone earning around ¥18 million to ¥20 million in total professional income would broadly sit around the reported median band for the dialysis medicine respondents. How strong is the dialysis medicine sample? The wider Physician Career Research Institute survey included 2,055 physicians, but the specialty-level dialysis medicine analysis was based on 20 respondents. That is an important limitation. The study only published specialty-level figures for specialties with at least 15 respondents, so dialysis medicine met the threshold for inclusion. However, 20 physicians remain a relatively small sample. The figures are therefore useful as a specialist benchmark, but they should not be treated as a definitive national estimate for every dialysis physician working in Japan. Individual income may vary considerably depending on: career stage; seniority; employer; working hours; geographic location; additional clinical roles; and the amount of side work undertaken. For dialysis physicians, the data are best used as one reference point rather than a guaranteed expectation. Is ¥19 million a salary figure? No. For dialysis physicians, the most important distinction is that the survey reports annual income including additional work, not a contractual basic salary. That makes it useful for answering: “What might my total annual professional income look like?” It is less suitable for answering: “What salary should a hospital offer me?” Those are different questions. A physician reviewing a new role in dialysis medicine should therefore consider both their guaranteed compensation and the potential additional income available through other clinical work. What should dialysis physicians take from the latest data? The 2025 survey provides two clear compensation benchmarks for physicians working in dialysis medicine in Japan. Median annual professional income, including side work, was: ¥19 million (approximately £91,000) And: 45.00% of respondents reported earning ¥20 million or more (approximately £96,000+). For a dialysis physician assessing their current income, these figures provide a useful indication of where their total annual earnings may sit relative to the surveyed group. However, the relatively small sample of 20 dialysis physicians means the figures should be interpreted cautiously. The most useful question is therefore not simply: “What is the salary for a dialysis physician in Japan?” It is: “What is my total annual professional income as a dialysis physician, including additional clinical work, and how does it compare with the ¥19 million benchmark?” That provides a more meaningful way for dialysis physicians to use the available compensation data. Source: Physician Career Research Institute / Mediwel, 2025 Physician Income Survey. Currency note: Sterling equivalents are approximate conversions using the JPY/GBP exchange rate on 11 September 2026. At that rate, ¥19 million is approximately £91,000 and ¥20 million approximately £96,000. GBP figures are included for reader context only and were not reported by the original Japanese survey. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • How Much Do Orthopaedic Surgeons Earn in Japan? 2025 Physician Income Data

    Orthopaedic surgeons in Japan reported a median annual income of ¥19 million (approximately £91,000) in the latest specialty-level physician income data from the Physician Career Research Institute. The findings come from a 2025 survey of 2,055 physicians conducted by Mediwel, with 139 orthopaedic surgeons represented in the specialty analysis. For orthopaedic surgeons specifically, the survey found: Median annual income: ¥19 million (approximately £91,000) Proportion earning ¥20 million or more: 45.32% ¥20 million threshold: approximately £96,000 Orthopaedic surgery respondents: 139 Importantly, these figures represent annual income including additional or side work, rather than simply the salary received from a physician's main employer. What is the median income for an orthopaedic surgeon in Japan? The reported median annual income for orthopaedic surgeons was: ¥19 million (approximately £91,000) This means the midpoint of the income distribution for the orthopaedic surgeons surveyed fell within the income band represented by ¥19 million. It should not be interpreted as a contractual salary or guaranteed annual earnings. Instead, the survey is designed to provide a picture of physicians' total annual professional income, including earnings from additional employment or side work. For an orthopaedic surgeon assessing their own compensation, that distinction is important. A hospital salary alone may not represent the physician's complete annual earnings. Nearly half reported earning ¥20 million or more The survey provides another useful benchmark for orthopaedic surgeons. 45.32% of orthopaedic surgery respondents reported annual income of at least ¥20 million (approximately £96,000). In practical terms, that means close to one in two of the orthopaedic surgeons participating in the survey fell into the ¥20 million-plus income group. For an orthopaedic surgeon trying to understand whether their own compensation sits around the middle or towards the higher end of the reported income distribution, this is arguably as useful as the median itself. The two figures together provide a clearer picture: Median income: ¥19 million (approximately £91,000) Earning ¥20 million+ (approximately £96,000+): 45.32% Why does the survey include side work? One of the important characteristics of physician compensation in Japan is that earnings from a doctor's primary workplace do not necessarily represent their entire professional income. Physicians may undertake additional paid clinical work alongside their main position. This can include work at another hospital or clinic, additional shifts or other paid medical activity. The Physician Career Research Institute therefore reports specialty income including part-time work and side jobs. That means the ¥19 million figure should be interpreted as: total reported annual physician income rather than: base salary from an orthopaedic surgeon's main hospital or employer. This distinction becomes particularly important when comparing a personal employment contract with published compensation benchmarks. An orthopaedic surgeon receiving less than ¥19 million from their principal employer is not necessarily earning below the survey median once additional professional income is included. Likewise, the survey should not be used as evidence that an orthopaedic surgeon should expect a ¥19 million basic salary. How many orthopaedic surgeons were included? The specialty analysis included 139 orthopaedic surgeons. That gives this particular specialty a useful sample within the wider 2,055-physician survey. The survey only published specialty-level income figures for specialties with at least 15 respondents, helping to avoid presenting figures for extremely small groups. Among the orthopaedic surgery respondents, the median age was 47 years. This is relevant when interpreting the compensation data because physician earnings can be influenced by career stage, seniority, working arrangements and the amount of additional work undertaken. The survey therefore provides a useful market benchmark, but it does not mean every orthopaedic surgeon in Japan should expect the same income. What does the ¥19 million median actually mean? There is another methodological point that orthopaedic surgeons should understand before using the figure as a compensation benchmark. Survey participants did not provide income as an exact number. Instead, income was collected in ranges, such as: ¥18 million to ¥20 million The research then reports the midpoint of that income band. Therefore, the published ¥19 million median represents the midpoint of the relevant ¥18 million–¥20 million income category. It should consequently be regarded as an approximate compensation benchmark rather than an exact median calculated from individual salary amounts. Is this salary or total compensation? For an orthopaedic surgeon reviewing the data, the simplest interpretation is: It is total annual income, not basic salary. The survey includes side work and additional professional earnings. That makes it particularly useful for understanding what orthopaedic surgeons may actually receive across all their professional activities during a year. But it also means the figure should not be directly compared with an advertised hospital salary without accounting for the difference in definition. When evaluating an employment opportunity, an orthopaedic surgeon may therefore want to consider several separate questions: What is the salary from the principal employer? What additional paid clinical work is available? How many additional hours are required to generate that income? Are allowances or other payments included? What is the realistic total annual professional income? The ¥19 million benchmark is most useful when viewed in that broader compensation context. What should orthopaedic surgeons take from the 2025 data? For orthopaedic surgeons in Japan, there are two particularly useful compensation benchmarks from the latest specialty survey. The first is median total annual income: ¥19 million (approximately £91,000) The second is the proportion reporting income of at least ¥20 million: 45.32% earned ¥20 million or more (approximately £96,000+). These figures provide orthopaedic surgeons with a current reference point when considering their own professional earnings. However, they should be interpreted as total annual income including side work, rather than base salary. For an individual orthopaedic surgeon, actual income may vary considerably according to career stage, working arrangement, employer, workload and additional professional activity. The most useful question is therefore not simply: “What is an orthopaedic surgeon's salary in Japan?” It is: “What is my total annual professional income as an orthopaedic surgeon, and how does it compare with the latest ¥19 million benchmark?” For orthopaedic surgeons assessing their compensation in Japan, that provides a much more meaningful comparison. Source: Physician Career Research Institute / Mediwel, 2025 Physician Income Survey. The specialty-level analysis was published on 14 January 2026. Currency note: Sterling equivalents are approximate conversions using the JPY/GBP exchange rate on 11 September 2026. At that rate, ¥19 million equates to approximately £91,000 and ¥20 million to approximately £96,000. GBP figures are provided only for reader context and were not reported by the original survey. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • How Much Do GPs Earn in the UK? 2024/25 Earnings for Salaried and Contractor GPs

    General practitioners in the UK earned very different amounts depending on where they worked and whether they were salaried or working as contractors. The latest GP Earnings and Expenses Estimates for 2024/25, published by NHS England Digital, show that average income before tax ranged from around £111,200 in Northern Ireland to £124,200 in Scotland when looking at all GPs combined. The gap between salaried and contractor GPs was much larger. In England, for example, average income before tax was approximately: £164,200 for contractor GPs £74,800 for salaried GPs £121,700 across all GPs combined For GPs and family physicians comparing compensation across the UK, employment model appears to be one of the biggest factors affecting earnings. What is the average GP income in the UK? The latest figures show the following average income before tax for GPs in 2024/25: England All GPs: £121,700 Contractor GPs: £164,200 Salaried GPs: £74,800 Scotland All GPs: £124,200 Contractor GPs: £140,000 Salaried GPs: £76,100 Wales All GPs: £117,000 Contractor GPs: £134,900 Salaried GPs: £84,000 Northern Ireland All GPs: £111,200 Contractor GPs: £121,000 Salaried GPs: £76,600 These figures represent average income before tax rather than a published NHS salary scale. That distinction matters. What is the difference between a salaried GP and a contractor GP? A salaried GP is typically employed by a GP practice and receives a salary under an employment contract. A contractor GP, often a GP partner or practice owner, usually has a financial stake in the practice and receives income linked to the practice's earnings after allowable expenses. That helps explain why contractor earnings are significantly higher than salaried GP income in the latest data. In England, contractor GP income was more than twice the average salaried GP figure. The same pattern appears across all four UK nations. However, contractor income should not be interpreted in the same way as a standard salary. GP contractors may have greater responsibility for: practice staffing; premises and operating costs; business risk; service delivery; pension contributions; administrative responsibilities; and the overall financial performance of the practice. For that reason, the contractor figures are best understood as professional income rather than a simple employment salary. Which part of the UK pays GPs the most? Looking at all GPs combined, Scotland recorded the highest average income in 2024/25 at approximately £124,200. England followed at £121,700, with Wales at £117,000 and Northern Ireland at £111,200. The pattern changes slightly when salaried GPs are considered separately. Wales had the highest average salaried GP income at £84,000, compared with: England: £74,800 Scotland: £76,100 Northern Ireland: £76,600 For contractor GPs, England reported the highest figure at £164,200. This suggests that headline national averages can conceal important differences in both geography and employment model. Is GP income the same as GP salary? No. This is one of the most important distinctions in the dataset. The NHS England Digital figures are based on income before tax, derived from anonymised HMRC Self Assessment data. That means the figures are not directly comparable with a published NHS salary scale. For salaried GPs, the data reflect actual reported income. For contractor GPs, the figures reflect income associated with their professional practice after allowable expenses. The dataset may also capture income beyond a straightforward NHS salary, including private and other professional income where relevant. For that reason, the figures provide a broader picture of what GPs actually earned rather than simply showing contractual salary ranges. How reliable is the data? The GP Earnings and Expenses Estimates are one of the more authoritative sources available for understanding GP income in the UK. They are based on anonymised HMRC tax data rather than a voluntary salary survey. This gives the dataset an important advantage when compared with self-reported compensation surveys. However, the figures still need to be interpreted carefully. They are averages across large and diverse groups of GPs, and individual income can vary depending on factors such as: hours worked; full-time or part-time status; practice ownership; location; additional clinical work; private work; and individual practice performance. The figures should therefore be treated as market benchmarks rather than guaranteed earnings. What does this mean for GPs and family physicians? The biggest takeaway from the latest UK data is that there is no single answer to the question: "What does a GP earn in the UK?" A more useful question is: "What does a GP earn in my employment model and in my part of the UK?" The difference between a salaried GP and a contractor GP is substantial, and the regional variation is also meaningful. For doctors evaluating general practice as a career, considering a move between UK nations, or comparing salaried and partnership routes, those distinctions are likely to be more useful than a single national average. The latest 2024/25 figures provide a strong benchmark: £74,800 to £84,000 for salaried GPs depending on UK nation £121,000 to £164,200 for contractor GPs £111,200 to £124,200 across all GPs combined As with all physician compensation data, the value lies in understanding the context behind the number. For UK GPs, employment model appears to matter just as much as location. Source: NHS England Digital, GP Earnings and Expenses Estimates 2024/25. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Biocon secures 10-year pertuzumab supply partnership in Brazil

    Biocon has secured a 10-year pertuzumab supply partnership in Brazil under the country's Productive Development Partnership programme. Biocon, Bahiafarma and Bionovis received full allocation for pertuzumab supply, supporting long-term access to the HER2-targeted breast cancer therapy in the Brazilian market. Biocon is eligible for milestone payments and a share of programme revenues, making the agreement a significant long-term commercial partnership for its oncology biosimilars business. Field Content Alert Type Long-term supply partnership Company Biocon Partners Bahiafarma and Bionovis Product Pertuzumab Therapy Area(s) Oncology Indication HER2-positive breast cancer Geography Brazil Agreement Duration 10 years Programme Productive Development Partnership What Happened Biocon and its Brazilian partners received full allocation under a 10-year programme for the supply of pertuzumab. Why It Matters The agreement provides Biocon with a long-term commercial position in Brazil's oncology market and supports access to a major HER2-targeted therapy. Supporting Context Biocon is eligible for milestone payments and a share of programme revenues under the arrangement. Key Takeaway The 10-year pertuzumab partnership strengthens Biocon's oncology biosimilars footprint in Brazil. What to Watch Technology transfer, supply execution and milestone payments under the programme. Primary Source Biocon Relevant Date September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Novartis Phase III HARBOR trial of del-desiran misses primary endpoint in myotonic dystrophy type 1

    Novartis reports that the Phase III HARBOR study of del-desiran did not meet its primary endpoint in patients with myotonic dystrophy type 1. The trial failed to demonstrate a statistically significant improvement on the primary vHOT functional endpoint, although Novartis reported activity across a number of secondary and exploratory measures. The setback is significant because del-desiran is a central asset from Novartis' acquisition of Avidity Biosciences and had been positioned as a potential disease-modifying treatment for DM1. Field Content Alert Type Phase III clinical trial results Company Novartis Drug / Asset Delpacibart etedesiran (del-desiran) Trial HARBOR Development Stage Phase III Therapy Area(s) Neuromuscular disease Indication Myotonic dystrophy type 1 Primary Endpoint vHOT functional endpoint What Happened The Phase III HARBOR study did not achieve a statistically significant improvement on its primary vHOT endpoint. Why It Matters Del-desiran is a strategically important asset for Novartis following its acquisition of Avidity, making the Phase III miss a significant pipeline setback. Supporting Context Novartis reported activity across a number of secondary and exploratory measures despite the primary endpoint miss. Key Takeaway HARBOR missed its primary Phase III endpoint, creating uncertainty around the development path for del-desiran in DM1. What to Watch Full HARBOR results, regulatory discussions and Novartis' next development steps for del-desiran. Primary Source Novartis Relevant Date September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Transcenta and WuXi Biologics sign HiCB technology licensing and strategic collaboration

    Transcenta Therapeutics and WuXi Biologics have entered a strategic licensing collaboration covering Transcenta's HiCB continuous bioprocessing technologies and ExcelPro media platform. Under the agreement, WuXi Biologics receives a non-exclusive licence to use Transcenta's HiCB technologies, with Transcenta receiving RMB10 million upfront and potential additional milestone payments. The collaboration broadens commercial access to continuous bioprocessing technology and highlights growing investment in manufacturing productivity across biologics development. Field Content Alert Type Technology licensing agreement Companies Transcenta Therapeutics and WuXi Biologics Technology HiCB continuous bioprocessing technologies Additional Platform ExcelPro media Licence Type Non-exclusive Upfront Payment RMB10 million Additional Economics Potential milestone payments Industry Area Biologics manufacturing What Happened Transcenta granted WuXi Biologics a non-exclusive licence to its HiCB technologies and ExcelPro media platform as part of a strategic collaboration. Why It Matters The agreement supports wider adoption of continuous bioprocessing approaches designed to improve biologics manufacturing efficiency and productivity. Supporting Context Transcenta receives RMB10 million upfront and may receive additional milestone payments. Key Takeaway The collaboration commercialises Transcenta's manufacturing technology through one of the world's largest biologics development and manufacturing providers. What to Watch Deployment of HiCB across WuXi Biologics programmes and achievement of future milestones. Primary Source Transcenta Therapeutics / WuXi Biologics Relevant Date September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA expands Hyrnuo approval to first-line HER2-mutant non-small cell lung cancer

    The FDA has granted accelerated approval to Hyrnuo for first-line treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer carrying activating HER2/ERBB2 tyrosine kinase domain mutations. The decision expands the use of sevabertinib into the first-line setting for eligible patients with HER2-mutant non-small cell lung cancer. The approval provides a new targeted treatment option for this molecularly defined patient group and further supports routine HER2 mutation testing in advanced disease. Field Content Alert Type FDA accelerated approval Company Bayer Drug / Asset Hyrnuo (sevabertinib) Regulator U.S. Food and Drug Administration Indication Locally advanced or metastatic non-squamous non-small cell lung cancer Biomarker Activating HER2/ERBB2 tyrosine kinase domain mutations Treatment Setting First-line What Happened The FDA granted accelerated approval to Hyrnuo as a first-line treatment option for adults with locally advanced or metastatic non-squamous NSCLC harbouring activating HER2/ERBB2 TKD mutations. Why It Matters The approval expands access to a biomarker-directed therapy earlier in the treatment pathway for patients with HER2-mutant NSCLC. Supporting Context Hyrnuo had previously been approved in patients who had received prior systemic therapy, making this an expansion into the first-line setting. Key Takeaway Sevabertinib is now available as a first-line targeted treatment for eligible adults with HER2-mutant non-squamous NSCLC. What to Watch Confirmatory clinical data and uptake of HER2 mutation testing in first-line advanced NSCLC. Primary Source U.S. Food and Drug Administration Relevant Date 9 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page